Tilray (TLRY) Stock Research

Monday

Unusually active option classes on open August 3rd

Aug 3, 9:40 AM

Over a week ago

Tilray sees FY27 revenue over $1B, consensus $1.09B

TLRY

Jul 28, 4:48 PM

Tilray reports Q4 adjusted EPS 5c vs. 14c last year

TLRY

Jul 28, 4:45 PM

Tilray options imply 10.7% move in share price post-earnings

TLRY

Jul 28, 2:49 PM

Tilray price target lowered by $2 at TD Cowen, here's why

TLRY

Jul 14, 8:37 AM

Largest borrow rate increases among liquid names

Jul 7, 8:45 AM

Tilray acquires HelloMD, terms not disclosed

TLRY

Jun 29, 5:11 PM

Tilray Medical Germany launches ARX

TLRY

Jun 10, 6:31 AM

Unusually active option classes on open June 5th

Jun 5, 9:40 AM

Tilray call volume above normal and directionally bullish

TLRY

Jun 3, 12:05 PM

Roth views partial cannabis re-scheduling order as 'extremely favorable'

Apr 23, 1:01 PM

Trump Trade: Trump officials reclassify state-licensed medical marijuana

+12

Apr 23, 10:21 AM

Trump administration reclassifies state-licensed medical marijuana

Apr 23, 9:52 AM

Unusually active option classes on open April 23rd

Apr 23, 9:40 AM

Tilray trading resumes

TLRY

Apr 22, 11:59 AM

Trump administration expected to reclassify cannabis soon, Axios reports

Apr 22, 11:56 AM

Tilray trading halted, volatility trading pause

TLRY

Apr 22, 11:49 AM

Tilray call volume above normal and directionally bullish

TLRY

Apr 20, 1:25 PM

Tilray call volume above normal and directionally bullish

TLRY

Apr 6, 1:25 PM

Tilray price target lowered by C$3.50 at Canaccord

TLRY

Apr 2, 11:16 AM

Tilray just upgraded at Roth Capital, here's why

TLRY

Apr 1, 9:57 PM

Tilray price target lowered by $2 at Alliance Global, here's why

TLRY

Apr 1, 4:22 PM

Tilray price target lowered by $3 at TD Cowen, here's why

TLRY

Mar 30, 8:08 AM

Tilray partners with Magnum Ice Cream on Popsicle Hard flavored beverages

TLRY

Mar 26, 7:17 AM

Congressman introduces bill for cannabis businesses to list on stock exchanges

Mar 19, 11:16 AM

Global Footprint and International Reach: Tilray has a significant international presence, particularly in Europe for medical cannabis, allowing it to tap into diverse and emerging markets beyond just Canada.

Diversified Business Portfolio: Beyond core cannabis operations, Tilray owns a robust portfolio of craft beverage brands including beer and spirits, providing revenue diversification and stability outside the volatile cannabis market.

Leading Medical Cannabis Position: The company holds a strong position in the global medical cannabis sector, leveraging early mover advantages and established regulatory pathways in various international markets.

Regulatory Uncertainty: Shifting cannabis laws, particularly at the federal level in the US and in emerging international markets, create unpredictable operational and market access challenges for Tilray.

Intense Competition: The global cannabis market is highly competitive, featuring numerous licensed producers and an active illicit market, which can pressure Tilray's pricing, market share, and sales volumes.

Profitability Challenges: Despite efforts to streamline operations, Tilray has faced difficulties achieving consistent profitability due to high operating costs, marketing expenses, and market oversupply leading to price compression.